Page 6 of 12 – SEC Filing CUSIP No. 737010108 13G Page 8 of 12 Pages
Item 1(a). Name of Issuer: Portola Pharmaceuticals, Inc. Item 1(b). Address of Issuer’s Principal Executive Offices: 270 E. Grand Avenue South San Francisco, CA 94080 Item 2(a). Name of Person Filing: James E. Flynn, Deerfield Mgmt, L.P., Deerfield Management Company, L.P., Deerfield Partners, L.P., Deerfield International Master Fund, L.P., Deerfield Special Situations Fund, L.P. Item 2(b). Address of Principal Business Office, or if None, Residence: James E. Flynn, Deerfield Mgmt, L.P., Deerfield Management Company, L.P., Deerfield Partners, L.P., Deerfield International Master Fund, L.P., Deerfield Special Situations Fund, L.P., 780 Third Avenue, 37th Floor, New York, NY 10017 Item 2(c). Citizenship: Deerfield Mgmt, L.P., Deerfield Management Company, L.P., Deerfield Special Situations Fund, L.P. and Deerfield Partners, L.P. – Delaware limited partnerships; Deerfield International Master Fund, L.P. – British Virgin Islands limited partnership; James E. Flynn – United States citizen Item 2(d). Title of Class of Securities: Common Stock Item 2(e). CUSIP Number: 737010108 Item 3. If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:
(a) o Broker or dealer registered under Section 15 of the Exchange Act. (b) o Bank as defined in Section 3(a)(6) of the Exchange Act. (c) o Insurance company as defined in Section 3(a)(19) of the Exchange Act. (d) o Investment company registered under Section 8 of the Investment Company Act.
(e) o An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
(f) o An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);
Follow Portola Pharmaceuticals Inc (NASDAQ:PTLA)
Follow Portola Pharmaceuticals Inc (NASDAQ:PTLA)
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
| CUSIP No. | 737010108 | 13G | Page 8 of 12 Pages |
| Item 1(a). | Name of Issuer: | |
| Portola Pharmaceuticals, Inc. | ||
| Item 1(b). | Address of Issuer’s Principal Executive Offices: | |
| 270 E. Grand Avenue South San Francisco, CA 94080 | ||
| Item 2(a). | Name of Person Filing: | |
| James E. Flynn, Deerfield Mgmt, L.P., Deerfield Management Company, L.P., Deerfield Partners, L.P., Deerfield International Master Fund, L.P., Deerfield Special Situations Fund, L.P. | ||
| Item 2(b). | Address of Principal Business Office, or if None, Residence: | |
| James E. Flynn, Deerfield Mgmt, L.P., Deerfield Management Company, L.P., Deerfield Partners, L.P., Deerfield International Master Fund, L.P., Deerfield Special Situations Fund, L.P., 780 Third Avenue, 37th Floor, New York, NY 10017 | ||
| Item 2(c). | Citizenship: | |
| Deerfield Mgmt, L.P., Deerfield Management Company, L.P., Deerfield Special Situations Fund, L.P. and Deerfield Partners, L.P. – Delaware limited partnerships; Deerfield International Master Fund, L.P. – British Virgin Islands limited partnership; James E. Flynn – United States citizen | ||
| Item 2(d). | Title of Class of Securities: | |
| Common Stock | ||
| Item 2(e). | CUSIP Number: | |
| 737010108 | ||
| Item 3. | If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a: |
| (a) | o | Broker or dealer registered under Section 15 of the Exchange Act. | |
| (b) | o | Bank as defined in Section 3(a)(6) of the Exchange Act. | |
| (c) | o | Insurance company as defined in Section 3(a)(19) of the Exchange Act. | |
| (d) | o | Investment company registered under Section 8 of the Investment Company Act. |
| (e) | o | An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E); |
| (f) | o | An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F); |
Follow Portola Pharmaceuticals Inc (NASDAQ:PTLA)
Follow Portola Pharmaceuticals Inc (NASDAQ:PTLA)
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
